Targets & Mechanisms

Triplet brings a new strategy to Huntington’s disease

Unveils preclinical POC data for its first DNA damage repair target

Triplet unveils preclinical proof-of-concept data in Huntington’s disease for the company’s first DNA damage repair target.

Preclinical data suggest that with a new target and route of administration, Triplet’s antisense oligonucleotide for Huntington’s disease may be effective where others have fallen short. 

The Cambridge, Mass.-based company unveiled preclinical data for its first target — DNA damage repair gene MSH3 — at